Eric VIVIER
À propos
orcid.org/0000-0001-7022-8287
Education
– Doctor in Veterinary Medicine, 1987, Ecole Nationale Vétérinaire d’Alfort
– Ph. D., 1991, Université Paris-Saclay, France
– HDR, 1992, Université Paris-Saclay, France
– Postdoctoral fellow, 1989-1993, Harvard Medical School, Boston, USA
Current positions
– Professor of Immunology, Marseille Medical School and Assistance-Publique des Hôpitaux de Marseille (PU-PH Classe Exceptionnelle)
– Co-Director, Marseille Immunopole Profiling Platform, FOCIS Center of Excellence
– President, Paris Saclay Cancer Cluster, https://www.parissaclaycancercluster.org
– Professor, Ecole Polytechnique, Palaiseau, France
Appointments
1995-present: Head of the “Innate Lymphoid Cells” Lab., CIML, France
1996-present: Member of the Institut Universitaire de France (Junior and Senior)
2008-2017: Director of the CIML
Publications: total 435, h-Index: 136, > 75,000 citations
Selected Funding
– European Research Council Synergy Grant (2024-2030)
– European Research Council Advanced grants (2011-2016 and 2017-2022)
– European Research Council Proof of Concept Grant (2019-2021)
Industry
– Co-founder of Innate-Pharma (innate-pharma.fr)
Elected membership
– 2013: French National Academy of Medicine
– 2016: Henry Kunkel Society
– 2019: EMBO
– 2021: Académie Royale de Médecine de Belgique (foreign member)
Awards
1987: Médaille d’Argent, Ecole Nationale Vétérinaire d’Alfort
1996: National League against Cancer Award
1999: Tremplins Rhône-Poulenc Award for Biotech start-ups
1999: Lucien Tartois Award, Fondation pour la Recherche Médicale
2003: Jacques Oudin Award, French Society for Immunology
2004: Deutsche Gesellschaft fûr Immunologie / EFIS Award
2008: Fondation Del Duca Award, National Academy of Sciences
2010: Grand Prix Turpin in Oncology, National Academy of Science
2010: Grand Prix Charles Oberling in Oncology
2013: Prix Duquesne, National League against Cancer with Sophie Ugolini
2015-present: Highly Cited Researcher (hcr.clarivate.com)
2016: Chevalier, Légion d’Honneur
2021: Officier, Ordre National du Mérite
2021: Grand Prix Départemental pour la Recherche en Provence
2024: Officier, Palmes Académiques
2025: 53e Prix Fondation ARC Léopold Griffuel de Recherche translationnelle et clinique
/
Projets
Projet
2025
Treating Liver Metastases
Projet : TREATLIVMETS Les métastases hépatiques surviennent chez près de 50 % des patients atteints de cancer, en particulier dans […]
Eric VIVIER
Projet
2025
Treating Breast Cancer
Projet : Treating Breast Cancer Le cancer du sein est le cancer le plus fréquemment diagnostiqué chez les femmes dans […]
Emilie NARNI-MANCINELLI
Publications
2025
Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing.,
J Immunother Cancer 2025 Mar; 13(3): .
2024
Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities,
<i>Experimental Hematology & Oncology</i>, 2024, 13 (1), pp.114. <a target="_blank" href="https://dx.doi.org/10.1186/s40164-024-00578-4">⟨10.1186/s40164-024-00578-4⟩</a>.
2024
High-dimensional single-cell analysis of human natural killer cell heterogeneity,
<i>Nature Immunology</i>, 2024, 25 (8), pp.1474-1488. <a target="_blank" href="https://dx.doi.org/10.1038/s41590-024-01883-0">⟨10.1038/s41590-024-01883-0⟩</a>.
2024
New immune cell engagers for cancer immunotherapy.,
Nat Rev Immunol 2024 Jul; 24(7): 471-486.
2024
Natural killer cell therapies,
<i>Nature</i>, 2024, 626 (8000), pp.727-736. <a target="_blank" href="https://dx.doi.org/10.1038/s41586-023-06945-1">⟨10.1038/s41586-023-06945-1⟩</a>.
2024
On blood and tissue-resident natural killer cells,
<i>Immunity</i>, 2024, 57 (1), pp.6-8. <a target="_blank" href="https://dx.doi.org/10.1016/j.immuni.2023.12.013">⟨10.1016/j.immuni.2023.12.013⟩</a>.
2023
Germinal center-dependent and -independent immune responses of tumor-infiltrating B cells in human cancers.,
Cell Mol Immunol 2023 Sep; 20(9): 1040-1050.
2023
Natural killer cells and type 1 innate lymphoid cells in cancer,
<i>Seminars in Immunology</i>, 2023, 66, pp.101709. <a target="_blank" href="https://dx.doi.org/10.1016/j.smim.2022.101709">⟨10.1016/j.smim.2022.101709⟩</a>.
2023
C5a-C5aR1 Axis Blockade in Patients With Severe COVID-19: Contrasting Results of PANAMO and FORCE,
<i>Critical Care Medicine</i>, 2023, 51 (5), pp.e129-e130. <a target="_blank" href="https://dx.doi.org/10.1097/CCM.0000000000005796">⟨10.1097/CCM.0000000000005796⟩</a>.
2022
Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer,
<i>Frontiers in Immunology</i>, 2022, 13, <a target="_blank" href="https://dx.doi.org/10.3389/fimmu.2022.898745">⟨10.3389/fimmu.2022.898745⟩</a>.
2022
Advancing natural killer therapies against cancer,
<i>Cell</i>, 2022, 185 (9), pp.1451-1454. <a target="_blank" href="https://dx.doi.org/10.1016/j.cell.2022.04.006">⟨10.1016/j.cell.2022.04.006⟩</a>.
2021
Clues that natural killer cells help to control COVID,
<i>Nature</i>, 2021, 600 (7888), pp.226-227. <a target="_blank" href="https://dx.doi.org/10.1038/d41586-021-02778-y">⟨10.1038/d41586-021-02778-y⟩</a>.
2021
Correction: Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia.,
Cell Mol Immunol 2021 Nov; 18(11): 2578-2580.
2021
Single-cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression,
<i>Cell Reports Medicine</i>, 2021, 2 (8), pp.100353. <a target="_blank" href="https://dx.doi.org/10.1016/j.xcrm.2021.100353">⟨10.1016/j.xcrm.2021.100353⟩</a>.
2021
Reply to ‘Comment to: Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia’,
<i>Cellular and molecular immunology</i>, 2021, 18 (5), pp.1350-1352. <a target="_blank" href="https://dx.doi.org/10.1038/s41423-021-00678-9">⟨10.1038/s41423-021-00678-9⟩</a>.
2021
Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia.,
Cell Mol Immunol 2021 May; 18(5): 1290-1304.
2021
Tumor-Infiltrating Natural Killer Cells,
<i>Cancer Discovery</i>, 2021, 11 (1), pp.34-44. <a target="_blank" href="https://dx.doi.org/10.1158/2159-8290.CD-20-0655">⟨10.1158/2159-8290.CD-20-0655⟩</a>.
2021
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.,
Open Res Eur 2021 ; 1(): 107.
2021
ISACs take a Toll on tumors,
<i>Nature Cancer</i>, 2021, 2 (1), pp.12-13. <a target="_blank" href="https://dx.doi.org/10.1038/s43018-020-00152-x">⟨10.1038/s43018-020-00152-x⟩</a>.
2020
Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19,
<i>Cellular and molecular immunology</i>, 2020, 17 (9), pp.995-997. <a target="_blank" href="https://dx.doi.org/10.1038/s41423-020-0493-9">⟨10.1038/s41423-020-0493-9⟩</a>.
2020
Maternal diesel particle exposure promotes offspring asthma through NK cell–derived granzyme B,
<i>Journal of Clinical Investigation</i>, 2020, <a target="_blank" href="https://dx.doi.org/10.1172/JCI130324">⟨10.1172/JCI130324⟩</a>.
2019
Les cellules natural killer : des cibles prometteuses dans la thérapie contre le cancer,
<i>Médecine/Sciences</i>, 2019, 35 (12), pp.990-992. <a target="_blank" href="https://dx.doi.org/10.1051/medsci/2019195">⟨10.1051/medsci/2019195⟩</a>.
2019
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity,
<i>Cell</i>, 2019, 177 (7), pp.1701+. <a target="_blank" href="https://dx.doi.org/10.1016/j.cell.2019.04.041">⟨10.1016/j.cell.2019.04.041⟩</a>.
2019
Monalizumab: inhibiting the novel immune checkpoint NKG2A,
<i>Journal for Immunotherapy of Cancer</i>, 2019, 7 (1), <a target="_blank" href="https://dx.doi.org/10.1186/s40425-019-0761-3">⟨10.1186/s40425-019-0761-3⟩</a>.
2019
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies,
<i>Cell Reports</i>, 2019, 27 (8), pp.2411-2425. <a target="_blank" href="https://dx.doi.org/10.1016/j.celrep.2019.04.091">⟨10.1016/j.celrep.2019.04.091⟩</a>.
2019
Inherited IL-18BP deficiency in human fulminant viral hepatitis,
<i>Journal of Experimental Medicine</i>, 2019, 216 (8), pp.1777-1790. <a target="_blank" href="https://dx.doi.org/10.1084/jem.20190669">⟨10.1084/jem.20190669⟩</a>.
2018
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells,
<i>Cell</i>, 2018, 175 (7), pp.1731-1743.e13. <a target="_blank" href="https://dx.doi.org/10.1016/j.cell.2018.10.014">⟨10.1016/j.cell.2018.10.014⟩</a>.
2018
A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets,
<i>OncoImmunology</i>, 2018, 7 (10), pp.e1475875. <a target="_blank" href="https://dx.doi.org/10.1080/2162402X.2018.1475875">⟨10.1080/2162402X.2018.1475875⟩</a>.
2018
Activating and inhibitory receptors expressed on innate lymphoid cells,
<i>Seminars in Immunopathology</i>, 2018, 40 (4, SI), pp.331-341. <a target="_blank" href="https://dx.doi.org/10.1007/s00281-018-0685-x">⟨10.1007/s00281-018-0685-x⟩</a>.
2017
Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency,
<i>Journal of Clinical Investigation</i>, 2017, 127 (5), pp.1991-2006. <a target="_blank" href="https://dx.doi.org/10.1172/JCI90727">⟨10.1172/JCI90727⟩</a>.
2017
FHL2 regulates natural killer cell development and activation during Streptococcus pneumoniae infection,
<i>Frontiers in Immunology</i>, 2017, 8, pp.123. <a target="_blank" href="https://dx.doi.org/10.3389/fimmu.2017.00123">⟨10.3389/fimmu.2017.00123⟩</a>.
2016
Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30,
<i>Journal of Molecular Biology</i>, 2016, 428 (22), pp.4457-4466. <a target="_blank" href="https://dx.doi.org/10.1016/j.jmb.2016.09.011">⟨10.1016/j.jmb.2016.09.011⟩</a>.
2016
Evidence of innate lymphoid cell redundancy in humans,
<i>Nature Immunology</i>, 2016, 17 (11), pp.1291 - 1299. <a target="_blank" href="https://dx.doi.org/10.1038/ni.3553">⟨10.1038/ni.3553⟩</a>.
2016
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials,
<i>Journal for Immunotherapy of Cancer</i>, 2016, 4, <a target="_blank" href="https://dx.doi.org/10.1186/s40425-016-0118-0">⟨10.1186/s40425-016-0118-0⟩</a>.
2016
Complementarity and redundancy of IL-22-producing innate lymphoid cells,
<i>Nature Immunology</i>, 2016, 17 (2), pp.179-186. <a target="_blank" href="https://dx.doi.org/10.1038/ni.3332">⟨10.1038/ni.3332⟩</a>.
2016
NK Cell-Specific Gata3 Ablation Identifies the Maturation Program Required for Bone Marrow Exit and Control of Proliferation,
<i>Journal of Immunology</i>, 2016, 196 (4), pp.1753-1767. <a target="_blank" href="https://dx.doi.org/10.4049/jimmunol.1501593">⟨10.4049/jimmunol.1501593⟩</a>.
2016
The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15,
<i>Immunity</i>, 2016, 44 (1), pp.103-115. <a target="_blank" href="https://dx.doi.org/10.1016/j.immuni.2015.12.007">⟨10.1016/j.immuni.2015.12.007⟩</a>.
2015
Shed NKG2D ligand boosts NK cell immunity.,
Cell Res 2015 Jun; 25(6): 651-2.
2014
Delivering three punches to knockout intracellular bacteria.,
Cell 2014 Jun; 157(6): 1251-1252.
2013
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide,
<i>Science</i>, 2013, 342 (6161), pp.971-976. <a target="_blank" href="https://dx.doi.org/10.1126/science.1240537">⟨10.1126/science.1240537⟩</a>.
2012
NK cell genesis: a trick of the trail.,
<i>Immunity</i>, 2012, 36 (1), pp.1-3. <a target="_blank" href="https://dx.doi.org/10.1016/j.immuni.2012.01.001">⟨10.1016/j.immuni.2012.01.001⟩</a>.
2011
The ‘T-cell-ness’ of NK cells: unexpected similarities between NK cells and T cells.,
<i>International Immunology</i>, 2011, 23 (7), pp.427-31. <a target="_blank" href="https://dx.doi.org/10.1093/intimm/dxr035">⟨10.1093/intimm/dxr035⟩</a>.
2011
Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance.,
<i>Science Signaling</i>, 2011, 4 (167), pp.ra21. <a target="_blank" href="https://dx.doi.org/10.1126/scisignal.2001608">⟨10.1126/scisignal.2001608⟩</a>.
2011
Science Signaling Podcast: 5 April 2011.,
<i>Science Signaling</i>, 2011, 4 (167), pc7.
2010
B7-H6 : un nouveau signal d’alarme pour les cellules natural killer
B7-H6 : a novel alert signal for NK cells,
<i>Médecine/Sciences</i>, 2010, 26 (2), pp.119-20. <a target="_blank" href="https://dx.doi.org/10.1051/medsci/2010262119">⟨10.1051/medsci/2010262119⟩</a>.
2009
Maturation of mouse NK cells is a 4-stage developmental program.,
<i>Blood</i>, 2009, 113 (22), pp.5488-96. <a target="_blank" href="https://dx.doi.org/10.1182/blood-2008-10-187179">⟨10.1182/blood-2008-10-187179⟩</a>.
2009
Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin.,
Nat Immunol 2009 Jan; 10(1): 75-82.
2008
Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways.,
<i>Blood</i>, 2008, 111 (7), pp.3571-8. <a target="_blank" href="https://dx.doi.org/10.1182/blood-2007-07-100057">⟨10.1182/blood-2007-07-100057⟩</a>.
2008
Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling.,
<i>Genome Biology</i>, 2008, 9 (1), pp.R17. <a target="_blank" href="https://dx.doi.org/10.1186/gb-2008-9-1-r17">⟨10.1186/gb-2008-9-1-r17⟩</a>.
2007
Germ-line and rearranged Tcrd transcription distinguish bona fide NK cells and NK-like gammadelta T cells.,
<i>European Journal of Immunology</i>, 2007, 37 (6), pp.1442-52. <a target="_blank" href="https://dx.doi.org/10.1002/eji.200737354">⟨10.1002/eji.200737354⟩</a>.
2007
Dissection of the role of PfEMP1 and ICAM-1 in the sensing of plasmodium falciparum-infected erythrocytes by natural killer cells.,
<i>PLoS ONE</i>, 2007, 2 (2), pp.e228. <a target="_blank" href="https://dx.doi.org/10.1371/journal.pone.0000228">⟨10.1371/journal.pone.0000228⟩</a>.
2006
Natural killer cells and malaria.,
<i>Immunological Reviews</i>, 2006, 214, pp.251-63. <a target="_blank" href="https://dx.doi.org/10.1111/j.1600-065X.2006.00446.x">⟨10.1111/j.1600-065X.2006.00446.x⟩</a>.
2006
A novel dendritic cell subset involved in tumor immunosurveillance.,
<i>Nature Methods</i>, 2006, 12, pp.214-9.
2005
Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages.,
<i>American Journal of Pathology</i>, 2005, 166 (1), pp.275-86.
2005
Expression of MHC-class I receptors confers functional intraclonal heterogeneity to a reactive expansion of gamma delta T cells,
<i>European Journal of Immunology</i>, 2005, 35, pp.1896-905.
2005
NK cells : new insights on physiology and clinical implication in diseases.,
<i>La Revue de Médecine Interne</i>, 2005, 27, pp.465-472.
2000
Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin,
<i>Proceedings of the National Academy of Sciences of the United States of America</i>, 2000, 97 (7), pp.3400-3405. <a target="_blank" href="https://dx.doi.org/10.1073/pnas.97.7.340">⟨10.1073/pnas.97.7.340⟩</a>.
Financement
